| 2019 |
| 05/22 | 224 | 228 | 222 | 225 | +0.9% | 445,000 | 160億861万 | -6.25% |
| 05/21 | 229 | 229 | 223 | 223 | -1.76% | 385,300 | 158億4780万 | -7.47% |
| 05/20 | 232 | 234 | 226 | 227 | -1.3% | 288,400 | 161億3207万 | -5.81% |
| 05/17 | 229 | 233 | 228 | 230 | +1.32% | 376,000 | 163億4526万 | -4.96% |
| 05/16 | 232 | 234 | 227 | 227 | -2.16% | 465,300 | 161億3207万 | -6.2% |
| 05/15 | 235 | 238 | 228 | 232 | -2.52% | 793,400 | 164億8740万 | -4.53% |
| 05/14 | 15:00 2019年3月期決算短信〔日本基準〕(連結) |
| 05/14 | 15:00 営業外収益の計上に関するお知らせ |
| 05/14 | 235 | 241 | 228 | 238 | -0.83% | 757,700 | 169億1380万 | -2.06% |
| 05/13 | 10:00 殿町・リプロセル再生医療センターの開設について |
| 05/13 | 258 | 258 | 238 | 240 | -2.83% | 1,132,600 | 170億5593万 | -1.23% |
| 05/10 | 242 | 248 | 238 | 247 | +2.92% | 542,100 | 175億5339万 | +1.65% |
| 05/09 | 15:00 営業外費用(持分法による投資利益の減少)の計上及び2019年3月期通期個別業績予想と前期実績との差異に関するお知らせ |
| 05/09 | 252 | 252 | 240 | 240 | -5.14% | 654,300 | 170億5593万 | -1.23% |
| 05/08 | 242 | 258 | 238 | 253 | +2.85% | 976,900 | 179億7979万 | +4.12% |
| 05/07 | 248 | 248 | 244 | 246 | -0.4% | 490,400 | 174億8233万 | +1.23% |
| 04/26 | 244 | 250 | 239 | 247 | +2.07% | 406,500 | 175億5339万 | +1.65% |
| 04/25 | 15:00 Bioserve Biotechonologies India Pvt LtdとHanugen Therapeuticsとの遺伝子治療のためのオリゴヌクレオチドの製造のためのパートナーシップの締結のお知らせ |
| 04/25 | 241 | 246 | 240 | 242 | -0.82% | 369,900 | 171億9806万 | -0.41% |
| 04/24 | 239 | 244 | 237 | 244 | +2.09% | 535,400 | 173億4019万 | 0% |
| 04/23 | 249 | 250 | 237 | 239 | -5.53% | 818,100 | 169億8486万 | -2.05% |
| 04/22 | 252 | 260 | 251 | 253 | -0.78% | 598,300 | 179億7979万 | +3.27% |
| 04/19 | 248 | 262 | 245 | 255 | +4.08% | 1,181,000 | 181億2192万 | +4.08% |
| 04/18 | 236 | 276 | 233 | 245 | +2.08% | 3,484,700 | 174億1126万 | -0.41% |
| 04/17 | 239 | 241 | 235 | 240 | +0.84% | 354,300 | 170億5593万 | -2.83% |
| 04/16 | 241 | 244 | 238 | 238 | -1.65% | 206,000 | 169億1380万 | -3.64% |
| 04/15 | 233 | 243 | 233 | 242 | +1.26% | 448,600 | 171億9806万 | -2.42% |
| 04/12 | 248 | 248 | 238 | 239 | -2.45% | 417,500 | 169億8486万 | -3.63% |
| 04/11 | 248 | 250 | 242 | 245 | -0.41% | 346,200 | 174億1126万 | -1.21% |
| 04/10 | 239 | 246 | 239 | 246 | +1.65% | 270,000 | 174億8233万 | -1.2% |
| 04/09 | 246 | 246 | 239 | 242 | +0.83% | 291,700 | 171億9806万 | -3.2% |
| 04/08 | 15:00 REPROCELL USA Inc.におけるISO9001:2015認証取得のお知らせ |
| 04/08 | 241 | 243 | 238 | 240 | +0.42% | 218,900 | 170億5593万 | -4% |
| 04/05 | 237 | 241 | 234 | 239 | +0.84% | 336,200 | 169億8486万 | -4.78% |
| 04/04 | 238 | 242 | 233 | 237 | -0.42% | 405,600 | 168億4273万 | -5.58% |
| 04/03 | 236 | 241 | 234 | 238 | +1.71% | 323,100 | 169億1380万 | -5.56% |
| 04/02 | 243 | 245 | 234 | 234 | -4.1% | 641,500 | 166億2953万 | -7.51% |
| 04/01 | 246 | 248 | 240 | 244 | +0.83% | 371,900 | 173億4019万 | -3.94% |
| 03/29 | 244 | 244 | 239 | 242 | 0% | 246,100 | 171億9806万 | -5.1% |
| 03/28 | 246 | 246 | 238 | 242 | -3.2% | 465,200 | 171億9806万 | -5.1% |
| 03/27 | 251 | 253 | 244 | 250 | +1.63% | 537,800 | 177億6659万 | -1.96% |
| 03/26 | 242 | 248 | 241 | 246 | +3.8% | 391,600 | 174億8233万 | -3.53% |
| 03/25 | 244 | 245 | 236 | 237 | -5.58% | 735,000 | 168億4273万 | -7.06% |
| 03/22 | 259 | 260 | 251 | 251 | -3.46% | 520,800 | 178億3766万 | -1.18% |
| 03/20 | 259 | 263 | 257 | 260 | 0% | 505,600 | 184億7726万 | +3.17% |
| 03/19 | 267 | 267 | 258 | 260 | -1.89% | 518,300 | 184億7726万 | +3.59% |
| 03/18 | 265 | 265 | 258 | 265 | +2.32% | 560,300 | 188億3259万 | +6.43% |
| 03/15 | 263 | 272 | 259 | 259 | -2.63% | 1,087,400 | 184億619万 | +4.86% |
| 03/14 | 264 | 268 | 258 | 266 | +0.76% | 786,100 | 189億366万 | +8.13% |
| 03/13 | 254 | 265 | 254 | 264 | +2.33% | 890,300 | 187億6152万 | +8.2% |
| 03/12 | 252 | 265 | 248 | 258 | +4.03% | 1,171,300 | 183億3512万 | +6.61% |
| 03/11 | 246 | 251 | 240 | 248 | +0.81% | 656,100 | 176億2446万 | +3.33% |
| 03/08 | 245 | 248 | 242 | 246 | -1.99% | 748,200 | 174億8233万 | +2.93% |
| 03/07 | 257 | 259 | 249 | 251 | -3.83% | 822,400 | 178億3766万 | +5.46% |
| 03/06 | 275 | 277 | 259 | 261 | +0.77% | 1,729,000 | 185億4832万 | +10.59% |
| 03/05 | 254 | 260 | 252 | 259 | +0.39% | 589,000 | 184億619万 | +10.21% |
| 03/04 | 259 | 264 | 257 | 258 | 0% | 797,700 | 183億3512万 | +10.73% |
| 03/01 | 263 | 272 | 255 | 258 | +4.45% | 2,338,500 | 183億3512万 | +11.21% |
| 02/28 | 15:00 米国の主要ながん研究施設Fox Chase Cancer Centerとの合弁会社への出資に関するお知らせ |
| 02/28 | 264 | 265 | 247 | 247 | -5.73% | 1,089,000 | 175億5339万 | +6.93% |
| 02/27 | 257 | 264 | 251 | 262 | +1.95% | 1,090,800 | 186億1939万 | +13.91% |
| 02/26 | 268 | 268 | 253 | 257 | -4.1% | 1,509,100 | 182億6406万 | +12.23% |
| 02/25 | 254 | 271 | 252 | 268 | +6.77% | 1,655,800 | 190億4579万 | +18.06% |
| 02/22 | 262 | 264 | 250 | 251 | -4.2% | 1,513,700 | 178億3766万 | +11.06% |
| 02/21 | 247 | 264 | 246 | 262 | +9.62% | 3,831,200 | 186億1939万 | +16.44% |
| 02/20 | 246 | 251 | 238 | 239 | -3.63% | 1,975,000 | 169億8486万 | +6.7% |
| 02/19 | 245 | 284 | 244 | 248 | +8.77% | 16,408,000 | 176億2446万 | +11.21% |
| 02/18 | 220 | 230 | 219 | 228 | +4.59% | 684,000 | 162億313万 | +2.7% |
| 02/15 | 216 | 222 | 213 | 218 | +0.93% | 375,000 | 154億9247万 | -1.36% |
| 02/14 | 231 | 231 | 215 | 216 | -4% | 662,500 | 153億5034万 | -2.26% |
| 02/13 | 15:00 営業外収益の計上に関するお知らせ |
| 02/13 | 15:00 2019年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/13 | 220 | 227 | 218 | 225 | +1.81% | 361,700 | 159億8993万 | +1.81% |
| 02/12 | 217 | 221 | 216 | 221 | +4.25% | 323,600 | 157億567万 | +0.45% |
| 02/08 | 215 | 217 | 210 | 212 | -1.85% | 401,400 | 150億6607万 | -3.2% |
| 02/07 | 222 | 223 | 215 | 216 | -2.26% | 411,900 | 153億5034万 | -1.37% |
| 02/06 | 223 | 225 | 220 | 221 | 0% | 257,700 | 157億567万 | +1.38% |
| 02/05 | 225 | 228 | 220 | 221 | +1.84% | 580,100 | 157億567万 | +2.31% |
| 02/04 | 15:00 瑞太生物技術（上海）有限会社との中国における販売業務提携のお知らせ |
| 02/04 | 214 | 222 | 214 | 217 | 0% | 357,500 | 154億2140万 | +1.4% |
| 02/01 | 218 | 218 | 212 | 217 | +1.4% | 300,400 | 154億2140万 | +1.88% |
| 01/31 | 216 | 217 | 213 | 214 | +2.39% | 290,700 | 152億820万 | +0.94% |
| 01/30 | 220 | 221 | 208 | 209 | -6.28% | 689,200 | 148億5287万 | -1.42% |
| 01/29 | 223 | 224 | 218 | 223 | -0.45% | 299,700 | 158億4780万 | +5.19% |
| 01/28 | 234 | 234 | 223 | 224 | -3.03% | 362,200 | 159億1887万 | +5.66% |
| 01/25 | 230 | 234 | 228 | 231 | 0% | 389,500 | 164億1633万 | +8.96% |
| 01/24 | 223 | 232 | 222 | 231 | +3.13% | 291,500 | 164億1633万 | +8.96% |
| 01/23 | 218 | 226 | 218 | 224 | +0.45% | 342,100 | 159億1887万 | +5.66% |
| 01/22 | 222 | 227 | 217 | 223 | 0% | 497,600 | 158億4780万 | +5.19% |
| 01/21 | 15:00 分担企業として参加するAMED公募事業の平成29年度補助金交付額確定に関するお知らせ |
| 01/21 | 238 | 239 | 223 | 223 | -5.51% | 788,800 | 158億4780万 | +4.69% |
| 01/18 | 231 | 237 | 229 | 236 | +1.72% | 524,900 | 167億7166万 | +10.8% |
| 01/17 | 225 | 233 | 224 | 232 | +4.04% | 1,075,600 | 164億8740万 | +8.92% |
| 01/16 | 218 | 227 | 217 | 223 | +2.29% | 570,800 | 158億4780万 | +4.21% |
| 01/15 | 214 | 222 | 211 | 218 | +0.46% | 587,400 | 154億9247万 | +0.93% |
| 01/11 | 220 | 221 | 214 | 217 | 0% | 523,800 | 154億2140万 | -0.46% |
| 01/10 | 208 | 217 | 207 | 217 | +2.36% | 775,300 | 154億2140万 | -1.36% |
| 01/09 | 218 | 222 | 209 | 212 | -1.85% | 801,900 | 150億6607万 | -4.07% |
| 01/08 | 209 | 218 | 209 | 216 | +4.35% | 706,900 | 153億5034万 | -3.14% |
| 01/07 | 210 | 212 | 204 | 207 | +3.5% | 763,400 | 147億1074万 | -7.59% |
| 01/04 | 186 | 201 | 186 | 200 | +4.71% | 709,100 | 142億1327万 | -11.5% |
| 2018 |
| 12/28 | 186 | 192 | 186 | 191 | 0% | 592,100 | 135億7368万 | -15.86% |
| 12/27 | 189 | 193 | 186 | 191 | +4.95% | 891,400 | 135億7368万 | -16.59% |
| 12/26 | 180 | 186 | 177 | 182 | +6.43% | 950,900 | 129億3408万 | -21.21% |
| 12/25 | 16:20 再生医療製品ステムカイマルの希少疾病用再生医療等製品への指定 |
| 12/25 | 170 | 179 | 170 | 171 | -10% | 2,306,000 | 121億5235万 | -26.92% |
| 12/21 | 192 | 197 | 186 | 190 | -3.55% | 1,413,400 | 135億261万 | -19.83% |
| 12/20 | 209 | 210 | 195 | 197 | -6.19% | 1,313,300 | 140億7万 | -17.23% |
| 12/19 | 210 | 217 | 209 | 210 | -0.47% | 639,400 | 149億2394万 | -12.13% |
| 12/18 | 212 | 217 | 211 | 211 | -3.65% | 651,300 | 149億9500万 | -12.08% |
| 12/17 | 225 | 226 | 217 | 219 | -4.37% | 663,300 | 155億6353万 | -9.13% |
| 12/14 | 235 | 238 | 229 | 229 | -3.38% | 393,200 | 162億7420万 | -4.98% |
